

Mario U Mondelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8048227/mario-u-mondelli-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

214
papers

11,012
citations

52
h-index

100
g-index

265
ext. papers

13,053
ext. citations

7.3
avg, IF

6.55
L-index

| # | Paper | IF | Citations |
|-----|---|------|-----------|
| 214 | MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma.. <i>Onc Immunology</i> , 2022 , 11, 2035919 | 7.2 | 1 |
| 213 | Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1141-1152 | 3.7 | 1 |
| 212 | Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. <i>Human Genetics</i> , 2021 , 141, 147 | 6.3 | 3 |
| 211 | The polymorphism L412F in inhibits autophagy and is a marker of severe COVID-19 in males.. <i>Autophagy</i> , 2021 , 1-11 | 10.2 | 5 |
| 210 | High Frequencies of Functional Virus-Specific CD4 T Cells in SARS-CoV-2 Subjects With Olfactory and Taste Disorders. <i>Frontiers in Immunology</i> , 2021 , 12, 748881 | 8.4 | 1 |
| 209 | Genetic mechanisms of critical illness in COVID-19. <i>Nature</i> , 2021 , 591, 92-98 | 50.4 | 451 |
| 208 | EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 315-319 | 10.5 | 22 |
| 207 | Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. <i>EBioMedicine</i> , 2021 , 65, 103246 | 8.8 | 25 |
| 206 | Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Infections. <i>Journal of Clinical Medicine</i> , 2021 , 10, | 5.1 | 1 |
| 205 | Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. <i>ELife</i> , 2021 , 10, | 8.9 | 51 |
| 204 | Protective Role of a Variant on Severe COVID-19 Outcome in Young Males and Elderly Women. <i>Genes</i> , 2021 , 12, | 4.2 | 14 |
| 203 | Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021 , 53, 1603-1609 | 3.3 | |
| 202 | Severe COVID-19 in Hospitalized Carriers of Single Pathogenic Variants. <i>Journal of Personalized Medicine</i> , 2021 , 11, | 3.6 | 5 |
| 201 | Intermediate Repeats Confer Genetic Risk for Severe COVID-19 Pneumonia Independently of Age. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 7 |
| 200 | A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1443-1451 | 3.4 | 0 |
| 199 | Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients. <i>Hepatology</i> , 2021 , 73, 79-90 | 11.2 | 5 |
| 198 | Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing?. <i>Digestive and Liver Disease</i> , 2021 , 53, 456-460 | 3.3 | 1 |

| | | | |
|-----|---|------|-----|
| 197 | Low risk of SARS-CoV-2 transmission by fomites in real-life conditions. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e112 | 25.5 | 93 |
| 196 | Unique immunological profile in patients with COVID-19. <i>Cellular and Molecular Immunology</i> , 2021 , 18, 604-612 | 15.4 | 89 |
| 195 | Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research. <i>European Journal of Human Genetics</i> , 2021 , 29, 745-759 | 5.3 | 20 |
| 194 | Mapping the human genetic architecture of COVID-19. <i>Nature</i> , 2021 , | 50.4 | 162 |
| 193 | COVID vaccination and asthma exacerbation: might there be a link?. <i>International Journal of Infectious Diseases</i> , 2021 , 112, 243-246 | 10.5 | 4 |
| 192 | Liver Field during Immunotherapy of Hepatocellular Carcinoma: Some Like It Hot. <i>Gastroenterology</i> , 2021 , 161, 1065-1067 | 13.3 | 1 |
| 191 | Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients.. <i>Genes and Immunity</i> , 2021 , | 4.4 | 4 |
| 190 | Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo Covid19 Registry (SMACORE). <i>Microorganisms</i> , 2020 , 8, | 4.9 | 157 |
| 189 | Emergency Department and Out-of-Hospital Emergency System (112-AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. <i>Internal and Emergency Medicine</i> , 2020 , 15, 825-833 | 3.7 | 31 |
| 188 | Hepatocellular carcinoma and hepatitis C virus: which should be treated first? 2020 , 117-121 | | |
| 187 | Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. <i>Journal of Hospital Infection</i> , 2020 , | 6.9 | 39 |
| 186 | Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. <i>Journal of Hospital Infection</i> , 2020 , | 6.9 | 22 |
| 185 | Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. <i>Journal of Medical Virology</i> , 2020 , 92, 1724-1727 | 19.7 | 152 |
| 184 | SARS Cov-2 infection in a renal-transplanted patient: A case report. <i>American Journal of Transplantation</i> , 2020 , 20, 1882-1884 | 8.7 | 67 |
| 183 | Immune Mechanisms of Viral Clearance and Disease Pathogenesis During Viral Hepatitis 2020 , 821-850 | | 1 |
| 182 | Elimination of hepatitis C in Europe: can WHO targets be achieved?. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 818-823 | 9.5 | 18 |
| 181 | Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. <i>JHEP Reports</i> , 2020 , 2, 100113 | 10.3 | 280 |
| 180 | Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches. <i>Cancers</i> , 2020 , 12, | 6.6 | 19 |

| | | | |
|-----|---|------|-----|
| 179 | Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. <i>Eurosurveillance</i> , 2020 , 25, | 19.8 | 86 |
| 178 | Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1094.e1-1094.e5 | 9.5 | 86 |
| 177 | Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1569-1571 | 9.5 | 2 |
| 176 | ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. <i>European Journal of Human Genetics</i> , 2020 , 28, 1602-1614 | 5.3 | 132 |
| 175 | The obesity paradox: Analysis from the SMATteo COvid-19 REgistry (SMACORE) cohort. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020 , 30, 1920-1925 | 4.5 | 21 |
| 174 | An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. <i>Cancers</i> , 2020 , 12, | 6.6 | 6 |
| 173 | Expansion of atypical memory B cells is a prominent feature of COVID-19. <i>Cellular and Molecular Immunology</i> , 2020 , 17, 1101-1103 | 15.4 | 41 |
| 172 | Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. <i>JHEP Reports</i> , 2020 , 2, 100169 | 10.3 | 68 |
| 171 | Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy. <i>Pediatric Allergy and Immunology</i> , 2020 , 31, 72-74 | 4.2 | 3 |
| 170 | Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection. <i>Frontiers in Immunology</i> , 2019 , 10, 2290 | 8.4 | 3 |
| 169 | Decreased interferon- γ production by NK cells from KIR haplotype B carriers in hepatitis C virus infection. <i>Liver International</i> , 2019 , 39, 1237-1245 | 7.9 | 1 |
| 168 | RE: Effects of Long-Term Norfloxacin Therapy in Patients With Advanced Cirrhosis. <i>Gastroenterology</i> , 2019 , 156, 2352-2353 | 13.3 | 2 |
| 167 | Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 872-884 | 6.1 | 18 |
| 166 | Detection of Liver Steatosis With a Novel Ultrasound-Based Technique: A Pilot Study Using MRI-Derived Proton Density Fat Fraction as the Gold Standard. <i>Clinical and Translational Gastroenterology</i> , 2019 , 10, e00081 | 4.2 | 43 |
| 165 | Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 69, 1165-1179 | 11.2 | 31 |
| 164 | Hepatitis C: Is eradication possible?. <i>Liver International</i> , 2019 , 39, 416-426 | 7.9 | 47 |
| 163 | Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. <i>Pharmacoeconomics</i> , 2019 , 37, 255-266 | 4.4 | 8 |
| 162 | Defective NKp30-mediated function in hepatocellular carcinoma-infiltrating NK cells. <i>Journal of Hepatology</i> , 2018 , 68, S679-S680 | 13.4 | 2 |

| | | | |
|-----|---|------|----|
| 161 | Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis. <i>Clinical Immunology</i> , 2018 , 188, 31-37 | 9 | 6 |
| 160 | The benefits of hepatitis C virus cure: Every rose has thorns. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 320-328 | 3.4 | 11 |
| 159 | Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615 | 5.8 | 7 |
| 158 | Exosomes: multitask cargo carriers modulating innate immunity to viruses. <i>Cellular and Molecular Immunology</i> , 2017 , 14, 476-477 | 15.4 | |
| 157 | Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity. <i>Journal of Hepatology</i> , 2017 , 66, 1130-1137 | 13.4 | 17 |
| 156 | HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy. <i>Antiviral Therapy</i> , 2017 , 22, 365-368 | 1.6 | 6 |
| 155 | Natural history of HCV infection: what is the public health impact of untreated disease?. <i>Future Virology</i> , 2017 , 12, 9-12 | 2.4 | 1 |
| 154 | Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. <i>Journal of Hepatology</i> , 2017 , | 13.4 | 9 |
| 153 | Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434 | 18.8 | 13 |
| 152 | Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56 NK cells. <i>Journal of Hepatology</i> , 2017 , 67, 1148-1156 | 13.4 | 13 |
| 151 | Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. <i>Scientific Reports</i> , 2017 , 7, 16017 | 4.9 | 22 |
| 150 | The impact of hepatitis C virus outside the liver: Evidence from Asia. <i>Liver International</i> , 2017 , 37, 159-172 | 2.9 | 31 |
| 149 | Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7. <i>Antiviral Research</i> , 2017 , 137, 108-111 | 10.8 | 12 |
| 148 | Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. <i>Gut</i> , 2016 , 65, 1998-2006 | 19.2 | 35 |
| 147 | Accuracy of the ElastPQ Technique for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C: a "Real Life" Single Center Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2016 , 25, 331-5 | 1.4 | 34 |
| 146 | Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 1027-32 | 9.5 | 5 |
| 145 | Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals: a pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , 2015 , 27, 305-12 | 2.2 | 8 |
| 144 | Skewed B cells in chronic hepatitis C virus infection maintain their ability to respond to virus-induced activation. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 391-8 | 3.4 | 26 |

| | | | |
|-----|--|------|----|
| 143 | ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. <i>Pharmacology</i> , 2015 , 96, 163-6 | 2.3 | 2 |
| 142 | Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. <i>Journal of Viral Hepatitis</i> , 2015 , 22, 469-80 | 3.4 | 6 |
| 141 | NKp30 isoforms in patients with chronic hepatitis C virus infection. <i>Immunology</i> , 2015 , 146, 234-42 | 7.8 | 21 |
| 140 | Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. <i>Autoimmunity Reviews</i> , 2015 , 14, 889-96 | 13.6 | 43 |
| 139 | A Human Monoclonal Antibody against Hepatitis B Surface Antigen with Potent Neutralizing Activity. <i>PLoS ONE</i> , 2015 , 10, e0125704 | 3.7 | 17 |
| 138 | Management of infections pre- and post-liver transplantation: report of an AISF consensus conference. <i>Journal of Hepatology</i> , 2014 , 60, 1075-89 | 13.4 | 56 |
| 137 | Ultrasound point shear wave elastography assessment of liver and spleen stiffness: effect of training on repeatability of measurements. <i>European Radiology</i> , 2014 , 24, 1283-9 | 8 | 57 |
| 136 | HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN α and Ribavirin: a randomized controlled trial. <i>Journal of Viral Hepatitis</i> , 2014 , 21, 458-65 | 3.4 | 15 |
| 135 | Management of infections in cirrhotic patients: report of a consensus conference. <i>Digestive and Liver Disease</i> , 2014 , 46, 204-12 | 3.3 | 36 |
| 134 | P465 SVR IS ASSOCIATED WITH NO RISK REDUCTION OF HCC DEVELOPMENT IN PATIENTS WITH HCV-RELATED CIRRHOSIS. A PROSPECTIVE, UP-TO 23 YEARS, COHORT FOLLOW-UP STUDY. <i>Journal of Hepatology</i> , 2014 , 60, S224 | 13.4 | 5 |
| 133 | Different combinations of cytokines and activating receptor stimuli are required for human natural killer cell functional diversity. <i>Cytokine</i> , 2013 , 62, 58-63 | 4 | 13 |
| 132 | Reply to: "Flow cytometry makes all the difference". <i>Journal of Hepatology</i> , 2013 , 59, 910-1 | 13.4 | |
| 131 | Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and facilitates infection of CD4pos T cells and macrophages. <i>Retrovirology</i> , 2013 , 10, 154 | 3.6 | 29 |
| 130 | The Impact of Type of Liver Conditions on the Patients' Health Related Quality of Life. <i>Value in Health</i> , 2013 , 16, A500 | 3.3 | 3 |
| 129 | Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. <i>Journal of Hepatology</i> , 2013 , 59, 38-44 | 13.4 | 47 |
| 128 | Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 790-800 | 3.4 | 10 |
| 127 | Performance of liver stiffness measurements by transient elastography in chronic hepatitis. <i>World Journal of Gastroenterology</i> , 2013 , 19, 49-56 | 5.6 | 33 |
| 126 | Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. <i>Journal of Viral Hepatitis</i> , 2012 , 19, 623-34 | 3.4 | 9 |

| | | | |
|-----|---|------|-----|
| 125 | Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. <i>Hepatology</i> , 2012 , 56, 2125-33 | 11.2 | 452 |
| 124 | Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes. <i>PLoS ONE</i> , 2012 , 7, e45821 | 3.7 | 36 |
| 123 | Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. <i>Hepatology</i> , 2012 , 56, 841-9 | 11.2 | 83 |
| 122 | Natural killer cell functional dichotomy: a feature of chronic viral hepatitis?. <i>Frontiers in Immunology</i> , 2012 , 3, 351 | 8.4 | 28 |
| 121 | Performance of real-time strain elastography, transient elastography, and aspartate-to-platelet ratio index in the assessment of fibrosis in chronic hepatitis C. <i>American Journal of Roentgenology</i> , 2012 , 199, 19-25 | 5.4 | 47 |
| 120 | T-29 Early NK cell activation predicts successful treatment outcome in chronic HCV infection. <i>Digestive and Liver Disease</i> , 2011 , 43, S86 | 3.3 | 2 |
| 119 | HBV genotype must be included in treatment algorithm. <i>Journal of Hepatology</i> , 2011 , 54, 396 | 13.4 | 21 |
| 118 | Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. <i>Journal of Hepatology</i> , 2011 , 55, 53-60 | 13.4 | 120 |
| 117 | EASL Clinical Practice Guidelines: management of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2011 , 55, 245-64 | 13.4 | 983 |
| 116 | Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. <i>Hepatic Medicine: Evidence and Research</i> , 2011 , 3, 21-8 | 3.4 | 4 |
| 115 | A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. <i>Autoimmunity Reviews</i> , 2011 , 10, 714-9 | 13.6 | 55 |
| 114 | Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. <i>Digestive and Liver Disease</i> , 2010 , 42, 81-91 | 3.3 | 52 |
| 113 | Is response to antiviral treatment influenced by hepatitis B virus genotype?. <i>Journal of Hepatology</i> , 2010 , 52, 441-9 | 13.4 | 47 |
| 112 | Natural killer cells in viral hepatitis: facts and controversies. <i>European Journal of Clinical Investigation</i> , 2010 , 40, 851-63 | 4.6 | 67 |
| 111 | Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation. <i>Journal of Hepatology</i> , 2009 , 50, 314-22 | 13.4 | 17 |
| 110 | Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. <i>Journal of Hepatology</i> , 2009 , 50, 1142-54 | 13.4 | 166 |
| 109 | Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. <i>Gastroenterology</i> , 2009 , 137, 1151-60, 1160.e1-7 | 13.3 | 318 |
| 108 | PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. <i>Journal of Clinical Investigation</i> , 2009 , 119, 551-64 | 15.9 | 233 |

| | | | |
|-----|--|------|-----|
| 107 | Hepatitis A acute liver failure: follow-up of paediatric patients in southern Brazil. <i>Journal of Viral Hepatitis</i> , 2008 , 15 Suppl 2, 66-8 | 3.4 | 21 |
| 106 | Treatment of chronic hepatitis B: recommendations from an Italian workshop. <i>Digestive and Liver Disease</i> , 2008 , 40, 603-17 | 3.3 | 44 |
| 105 | Eltrombopag: an effective remedy for thrombocytopaenia?. <i>Journal of Hepatology</i> , 2008 , 48, 1030-2 | 13.4 | 1 |
| 104 | Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay. <i>Journal of Viral Hepatitis</i> , 2008 , 15, 66-70 | 3.4 | 3 |
| 103 | Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. <i>Hepatology</i> , 2007 , 46, 1350-6 | 11.2 | 141 |
| 102 | Reply:. <i>Hepatology</i> , 2007 , 47, 357-358 | 11.2 | |
| 101 | Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls. <i>Journal of Virology</i> , 2007 , 81, 4564-71 | 6.6 | 15 |
| 100 | Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006 , 43, 64-71 | 11.2 | 147 |
| 99 | Viral and host immune regulatory mechanisms in hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2006 , 18, 327-31 | 2.2 | 13 |
| 98 | Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2005 , 42, 41-6 | 13.4 | 140 |
| 97 | Acute hepatitis C: diagnosis and management. <i>Journal of Hepatology</i> , 2005 , 42 Suppl, S108-14 | 13.4 | 54 |
| 96 | Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. <i>Journal of Experimental Medicine</i> , 2005 , 202, 817-28 | 16.6 | 177 |
| 95 | Dissociation of serum and liver hepatitis C virus RNA levels in patients coinfecting with human immunodeficiency virus and treated with antiretroviral drugs. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3012-6 | 9.7 | 3 |
| 94 | Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. <i>Gut</i> , 2004 , 53, 1673-81 | 19.2 | 77 |
| 93 | Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanisms. <i>European Journal of Immunology</i> , 2004 , 34, 427-37 | 6.1 | 58 |
| 92 | Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: the role of the virus. <i>European Journal of Immunology</i> , 2004 , 34, 438-46 | 6.1 | 47 |
| 91 | Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. <i>Cancer Letters</i> , 2004 , 208, 75-9 | 9.9 | 24 |
| 90 | Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts?. <i>Journal of Hepatology</i> , 2004 , 40, 536-8 | 13.4 | 13 |

| | | | |
|----|---|------|-----|
| 89 | Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. <i>Journal of Hepatology</i> , 2004 , 41, 474-81 | 13.4 | 83 |
| 88 | Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection. <i>Journal of Clinical Investigation</i> , 2004 , 113, 963-972 | 15.9 | 229 |
| 87 | Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. <i>Journal of Clinical Investigation</i> , 2004 , 113, 963-72 | 15.9 | 103 |
| 86 | Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses. <i>Journal of Biosciences</i> , 2003 , 28, 305-10 | 2.3 | 12 |
| 85 | Multifaceted functions of B cells in chronic hepatitis C virus infection. <i>Antiviral Research</i> , 2003 , 60, 111-5 | 10.8 | 6 |
| 84 | CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. <i>International Journal of Cancer</i> , 2003 , 104, 310-7 | 7.5 | 55 |
| 83 | Hepatitis C virus: simply too smart to be just a liver pathogen. <i>Digestive and Liver Disease</i> , 2003 , 35, 760-3 | 3.3 | |
| 82 | Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients. <i>Journal of Hepatology</i> , 2003 , 39, 564-70 | 13.4 | 22 |
| 81 | Monitoring response to antiviral therapy for patients with chronic hepatitis C virus infection by a core-antigen assay. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 3881-4 | 9.7 | 16 |
| 80 | Kinetics and significance of serum hepatitis C virus core antigen in patients with acute hepatitis C. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 2144-6 | 9.7 | 21 |
| 79 | Natural history of hepatitis C virus infection. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2003 , 17, 128-32 | 0.7 | 1 |
| 78 | Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. <i>Hepatology</i> , 2002 , 36, 195-201 | 11.2 | 49 |
| 77 | Construction and characterization of an intracellular single-chain human antibody to hepatitis C virus non-structural 3 protein. <i>Journal of Hepatology</i> , 2002 , 37, 660-8 | 13.4 | 18 |
| 76 | Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?. <i>Antiviral Research</i> , 2001 , 52, 153-9 | 10.8 | 42 |
| 75 | Induction of cross-reactive humoral immune response by immunization with mimotopes of the hypervariable region 1 of the hepatitis C virus. <i>International Reviews of Immunology</i> , 2001 , 20, 289-300 | 4.6 | 12 |
| 74 | Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles. <i>Journal of Immunology</i> , 2001 , 167, 3878-86 | 5.3 | 28 |
| 73 | Hepatitis C virus genotypes and risk of cirrhosis in southern Italy. <i>Clinical Infectious Diseases</i> , 2001 , 33, 70-5 | 11.6 | 12 |
| 72 | Is the natural history of hepatitis C virus carriers with normal aminotransferase really benign?. <i>Gastroenterology</i> , 2001 , 121, 1526-7 | 13.3 | 31 |

| | | | |
|----|--|------|-----|
| 71 | Mimotopes of the hyper variable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. <i>Molecular Immunology</i> , 2001 , 38, 485-92 | 4.3 | 27 |
| 70 | Neonatal blood microtransfusions and hepatitis C virus infection. <i>Lancet, The</i> , 2001 , 357, 1363 | 4.0 | |
| 69 | Hepatitis C is more severe in drug users with human immunodeficiency virus infection. <i>Journal of Viral Hepatitis</i> , 2000 , 7, 297-301 | 3.4 | 32 |
| 68 | Immunopathogenesis of viral hepatitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2000 , 18, 141-66 | 12.3 | 2 |
| 67 | Occult hepatitis B virus infection. <i>Digestive and Liver Disease</i> , 2000 , 32, 822-6 | 3.3 | 22 |
| 66 | Natural history of hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000 , 15 Suppl, E105-10 | 4 | 29 |
| 65 | Production of human monoclonal antibodies to hepatitis C virus and their characterization. <i>Methods in Molecular Medicine</i> , 1999 , 19, 451-61 | | 2 |
| 64 | GB virus type C infection in patients treated for childhood acute lymphoblastic leukemia. <i>Transfusion</i> , 1999 , 39, 212-7 | 2.9 | 3 |
| 63 | Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction. <i>Hepatology</i> , 1999 , 29, 536-42 | 11.2 | 57 |
| 62 | Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. <i>Hepatology</i> , 1999 , 29, 1272-9 | 11.2 | 80 |
| 61 | Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation. <i>Hepatology</i> , 1999 , 30, 537-45 | 11.2 | 49 |
| 60 | Clinical significance of hepatitis C virus genotypes. <i>Journal of Hepatology</i> , 1999 , 31 Suppl 1, 65-70 | 13.4 | 81 |
| 59 | Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study. <i>Journal of Clinical Microbiology</i> , 1999 , 37, 2371-2 | 9.7 | 17 |
| 58 | Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. <i>EMBO Journal</i> , 1998 , 17, 3521-33 | 13.3 | 121 |
| 57 | Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. <i>Hepatology</i> , 1998 , 27, 1678-86 | 11.2 | 48 |
| 56 | Hepatitis C. <i>Lancet, The</i> , 1998 , 351, 1209 | 4.0 | |
| 55 | Antibody-negative chronic hepatitis C virus infection in immunocompetent children. <i>Journal of Pediatrics</i> , 1998 , 132, 1048-50 | 3.6 | 8 |
| 54 | Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications. <i>Journal of Hepatology</i> , 1998 , 29, 879-86 | 13.4 | 12 |

| | | | |
|----|---|------|-----|
| 53 | HGV/GBV-C infection in liver transplant recipients: antibodies to the viral E2 envelope glycoprotein protect from de novo infection. <i>Journal of Hepatology</i> , 1998 , 29, 533-40 | 13.4 | 8 |
| 52 | Association between HLA class II alleles and protection from or susceptibility to chronic hepatitis C. <i>Journal of Hepatology</i> , 1998 , 28, 1-7 | 13.4 | 82 |
| 51 | Identification of HCV core mimotopes: improved methods for the selection and use of disease-related phage-displayed peptides. <i>Biological Chemistry</i> , 1997 , 378, 495-502 | 4.5 | 8 |
| 50 | A survey of hepatitis C virus infection in haemodialysis patients over a 7-year follow-up. <i>Nephrology Dialysis Transplantation</i> , 1997 , 12, 2208-10 | 4.3 | 0 |
| 49 | Role for CD4 positive T cell response in the pathogenesis of hepatitis B. <i>Journal of Hepatology</i> , 1997 , 26, 1157-8 | 13.4 | 1 |
| 48 | Reply to Pape and Jung. <i>Journal of Hepatology</i> , 1997 , 26, 1158 | 13.4 | |
| 47 | Epidemiology of hepatitis C virus infection in an area of Southern Italy. <i>Journal of Hepatology</i> , 1997 , 27, 30-5 | 13.4 | 71 |
| 46 | Hepatitis C virus infection among institutionalised psychiatric patients: a regression analysis of indicators of risk. <i>Journal of Hepatology</i> , 1997 , 27, 455-63 | 13.4 | 30 |
| 45 | Recombinant human antibodies specific for hepatitis C virus proteins. <i>Archives of Virology</i> , 1997 , 142, 601-10 | 2.6 | 2 |
| 44 | Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. <i>Hepatology</i> , 1997 , 25, 754-8 | 11.2 | 290 |
| 43 | Antibody responses to the hepatitis C virus E2 protein: Relationship to viraemia and prevalence in anti-HCV seronegative subjects. <i>Journal of Medical Virology</i> , 1997 , 51, 1-5 | 19.7 | 25 |
| 42 | A longitudinal analysis of hepatitis C virus replication following liver transplantation. <i>Gastroenterology</i> , 1996 , 110, 167-77 | 13.3 | 410 |
| 41 | Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. <i>Gastroenterology</i> , 1996 , 111, 199-205 | 13.3 | 138 |
| 40 | Is there a role for immune responses in the pathogenesis of hepatitis C?. <i>Journal of Hepatology</i> , 1996 , 25, 232-8 | 13.4 | 15 |
| 39 | Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C. <i>Digestive Diseases and Sciences</i> , 1995 , 40, 2595-601 | 4 | 16 |
| 38 | A human antibody specific for hepatitis C virus core protein: synthesis in a bacterial system and characterization. <i>Gene</i> , 1995 , 164, 203-9 | 3.8 | 12 |
| 37 | Molecular epidemiology of hepatitis C virus infection among intravenous drug users. <i>Journal of Hepatology</i> , 1995 , 22, 691-5 | 13.4 | 62 |
| 36 | Vertical transmission of hepatitis C. <i>Lancet, The</i> , 1995 , 345, 1122-1123 | 40 | 24 |

| | | | |
|----|---|------|-----|
| 35 | Role of humoral immune responses in hepatitis B and C virus infections. <i>European Journal of Clinical Investigation</i> , 1995 , 25, 543-7 | 4.6 | 3 |
| 34 | Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. <i>Hepatology</i> , 1995 , 21, 285-290 | 11.2 | 157 |
| 33 | Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients. <i>Journal of Virology</i> , 1995 , 69, 4407-12 | 6.6 | 66 |
| 32 | Optimization for the detection of hepatitis C virus antigens in the liver. <i>Journal of Hepatology</i> , 1994 , 20, 143-7 | 13.4 | 48 |
| 31 | Hepatitis C virus (HCV) core serotypes in chronic HCV infection. <i>Journal of Clinical Microbiology</i> , 1994 , 32, 2523-7 | 9.7 | 32 |
| 30 | Significance of the immune response to a major, conformational B-cell epitope on the hepatitis C virus NS3 region defined by a human monoclonal antibody. <i>Journal of Virology</i> , 1994 , 68, 4829-36 | 6.6 | 40 |
| 29 | Properties of a human monoclonal antibody specific for the NS4 region of hepatitis C virus. <i>Journal of Hepatology</i> , 1993 , 18, 163-7 | 13.4 | 4 |
| 28 | Immunobiology and pathogenesis of hepatitis C virus infection. <i>Research in Virology</i> , 1993 , 144, 269-74 | | 3 |
| 27 | Vertical transmission of hepatitis C virus and HIV. <i>Aids</i> , 1993 , 7, 1024-5 | 3.5 | 2 |
| 26 | Virological features of hepatitis C virus infection in hemodialysis patients. <i>Journal of Clinical Microbiology</i> , 1993 , 31, 2913-7 | 9.7 | 60 |
| 25 | High prevalence of hepatitis C virus genotype III infection in patients with normal liver enzymes and mild histologic lesions. <i>Hepatology</i> , 1993 , 18, A83 | 11.2 | 2 |
| 24 | High prevalence of antibodies to hepatitis C virus in hemodialysis units using a second generation assay. <i>Nephron</i> , 1992 , 61, 350-1 | 3.3 | 24 |
| 23 | Effect of Interleukin-4 on Cytolytic T Cells. <i>International Journal of Immunopathology and Pharmacology</i> , 1991 , 4, 39-45 | 3 | 2 |
| 22 | Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 1991 , 6, 480-3 | 4.3 | 43 |
| 21 | The emerging picture of hepatitis C. <i>Digestive Diseases</i> , 1991 , 9, 245-52 | 3.2 | 6 |
| 20 | The cellular immune response to nucleocapsid antigens in hepatitis B virus infection. <i>Seminars in Immunopathology</i> , 1990 , 12, 25-31 | | 8 |
| 19 | Autoimmune hepatitis in children and hepatitis C virus testing. <i>Lancet, The</i> , 1990 , 335, 1160-1 | 40 | 17 |
| 18 | Anti-HCV positive patients in dialysis units?. <i>Lancet, The</i> , 1990 , 336, 243-4 | 40 | 21 |

| | | | |
|----|--|---------|-----|
| 17 | Early US experience with anti-HCV kit in blood donors. <i>Lancet, The</i> , 1990 , 336, 244-5 | 40 | 50 |
| 16 | Retroviral-mediated transfer and expression of hepatitis B e antigen in human primary skin fibroblasts and Epstein-Barr virus-transformed B lymphocytes. <i>Virology</i> , 1989 , 168, 31-9 | 3.6 | 9 |
| 15 | Hepatitis B virus structure and biology. <i>Microbial Pathogenesis</i> , 1989 , 6, 311-25 | 3.8 | 68 |
| 14 | Detection of HTLV-III-specific IgG bands in the CSF from a patient with AIDS and encephalitis. <i>Neurology</i> , 1988 , 38, 143-4 | 6.5 | 20 |
| 13 | Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. <i>Liver</i> , 1987 , 7, 307-15 | | 57 |
| 12 | Differential distribution of hepatitis B core and E antigens in hepatocytes: analysis by monoclonal antibodies. <i>Hepatology</i> , 1986 , 6, 199-204 | 11.2 | 41 |
| 11 | In vitro effect of lymphoblastoid alpha-interferon on subpopulations of effector cells mediating cytotoxicity for autologous hepatocytes in hepatitis B and non-A, non-B. <i>International Journal of Immunopharmacology</i> , 1986 , 8, 887-91 | | 4 |
| 10 | Alpha-interferon enhances non-T cell cytotoxicity for autologous hepatocytes in acute and chronic HBV infection. <i>Journal of Hepatology</i> , 1986 , 3 Suppl 2, S279-81 | 13.4 | 2 |
| 9 | Immunopathological mechanisms of liver cell injury in chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 1986 , 3 Suppl 2, S17-23 | 13.4 | 23 |
| 8 | Different mechanisms responsible for in vitro cell-mediated cytotoxicity to autologous hepatocytes in children with autoimmune and HBsAg-positive chronic liver disease. <i>Journal of Pediatrics</i> , 1985 , 106, 899-906 | 3.6 | 12 |
| 7 | Mechanisms of liver cell injury in acute and chronic hepatitis B. <i>Seminars in Liver Disease</i> , 1984 , 4, 47-58 | 7.3 | 109 |
| 6 | Lymphocyte cytotoxicity to autologous hepatocytes in alpha 1-antitrypsin deficiency. <i>Gut</i> , 1984 , 25, 1044-9 | 4.2 | 16 |
| 5 | Relationship between expression of hepatitis B virus antigens in isolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 1984 , 4, 63-8 | 11.2 | 124 |
| 4 | Cyclosporin for Crohn's disease. <i>Lancet, The</i> , 1984 , 1, 1242 | 40 | 30 |
| 3 | Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males | | 2 |
| 2 | The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males | | 3 |
| 1 | Immune Mechanisms of Viral Clearance and Disease Pathogenesis During Viral Hepatitis | 835-857 | |